Paul Quinlan serves as General Counsel at Oruka Therapeutics Inc., a clinical-stage biotechnology company pioneering transformative treatments for vitiligo and other autoimmune skin diseases. With more than 25 years of experience in life sciences law, Paul oversees all legal, regulatory, and compliance functions at Oruka, providing strategic counsel to support the company's innovative pipeline, including its lead asset, OK-101, currently advancing through clinical trials. His role is pivotal in navigating complex biotech landscapes, from intellectual property protection and licensing agreements to corporate governance and partnerships that fuel Oruka's growth. Paul's distinguished career began at top-tier law firms such as Cooley LLP and Goodwin Procter LLP, where he specialized in mergers and acquisitions, venture financing, and securities law for emerging biotech companies. He later held senior legal positions at notable firms including Aduro Biotech and Five Prime Therapeutics, contributing to high-profile deals such as multi-hundred-million-dollar collaborations and successful IPOs. Among his key achievements, Paul orchestrated the legal framework for several blockbuster licensing agreements and played a crucial role in FDA regulatory submissions, earning recognition from industry peers for his pragmatic approach to risk management in high-stakes environments. Under Paul's leadership at Oruka, the company has secured substantial venture funding exceeding $100 million and forged strategic alliances with global pharmaceutical leaders, positioning it as a frontrunner in dermatology therapeutics. A graduate of Harvard Law School and holder of a B.A. from Stanford University, Paul is a sought-after advisor in the biotech sector, frequently speaking at conferences on legal challenges in drug development and innovation.